Get the Stockscreener App
15.40
0.10%
-0.025
Dynavax Technologies Corp stock is traded at $15.40, with a volume of 2.19M.
It is down -0.10% in the last 24 hours and up +41.55% over the past month.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
See More
Previous Close:
$15.43
Open:
$15.43
24h Volume:
2.19M
Relative Volume:
0.87
Market Cap:
$1.75B
Revenue:
$260.81M
Net Income/Loss:
$20.48M
P/E Ratio:
118.50
EPS:
0.13
Net Cash Flow:
$22.67M
1W Performance:
+0.23%
1M Performance:
+41.55%
6M Performance:
+49.66%
1Y Performance:
+20.15%
1-Day Range:
$15.41
$15.45
1-Week Range:
$15.37
$15.45
52-Week Range:
$9.20
$15.49
Dynavax Technologies Corp Stock (DVAX) Company Profile
Name
Dynavax Technologies Corp
Sector
Phone
(510) 848-5100
Address
2100 POWELL STREET, EMERYVILLE, CA
Compare DVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DVAX
Dynavax Technologies Corp
|
15.41 | 1.75B | 260.81M | 20.48M | 22.67M | 0.13 |
|
ZTS
Zoetis Inc
|
125.88 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.89 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.06 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
52.61 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-01-24 | Initiated | Goldman | Neutral |
| Sep-27-22 | Initiated | JMP Securities | Mkt Outperform |
| Jan-06-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Initiated | Goldman | Buy |
| Aug-07-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-20 | Initiated | Evercore ISI | Outperform |
| Oct-18-19 | Initiated | H.C. Wainwright | Buy |
| Jul-11-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-27-19 | Reiterated | Cantor Fitzgerald | Overweight |
| May-10-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-25-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-31-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-31-17 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Apr-28-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-27-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-13 | Upgrade | MLV & Co | Hold → Buy |
| Feb-25-13 | Downgrade | MLV & Co | Buy → Hold |
| Nov-16-12 | Reiterated | MLV & Co | Buy |
View All
Dynavax Technologies Corp Stock (DVAX) Latest News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—DVAX, FONR, DBRG, and ONTF - GlobeNewswire Inc.
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ - marketscreener.com
Evaluating Dynavax (DVAX) After Its Recent Share Price Rally: Is the Stock Still Undervalued? - simplywall.st
Pacer Advisors Inc. Grows Holdings in Dynavax Technologies Corporation $DVAX - MarketBeat
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - The Malaysian Reserve
Sanofi Acquires Emeryville's Dynavax Technologies for $2.2 Billion, Bolstering Vaccine Portfolio Amid Industry Optimism - Hoodline
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report - BioCentury
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - Business Wire
Dynavax (DVAX) rockets 38% on Sanofi $2-billion merger - MSN
Insider Selling: Dynavax Technologies (NASDAQ:DVAX) COO Sells 30,000 Shares of Stock - MarketBeat
Dynavax Technologies (NASDAQ:DVAX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Emeryville's Dynavax accepts $2.2 billion buyout from Sanofi following year of investor pressure - The Business Journals
Dynavax Technologies Signs Agreement and Plan of Merger With Sanofi - TradingView — Track All Markets
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection - GuruFocus
Small Cap Stocks To Keep An Eye OnDecember 25th - MarketBeat
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Insider Monkey
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal - MSN
Exchange Traded Concepts LLC Has $2 Million Stake in Dynavax Technologies Corporation $DVAX - MarketBeat
Dynavax Technologies (NASDAQ:DVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Small Cap Stocks To Follow TodayDecember 24th - MarketBeat
Biggest stock movers Wednesday: DVAX, NKE, INTC, and more - MSN
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Sahm
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday - Benzinga
Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger - Insider Monkey
Assessing Dynavax After a 42% Surge and Strong HEPLISAV B Growth in 2025 - Yahoo Finance
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why - Benzinga
NKE, OMER, MU, INTC, DVAX: 5 Trending Stocks TodayNike (NYSE:NKE) - Benzinga
Stock Movers: Intel, Dynavax, Snowflake - Bloomberg.com
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2 Billion in Cash Deal - USA Herald
Dynavax Stock Climbs: Is It Time to Ride the Wave? - StocksToTrade
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition - MedCity News
European Stocks Close Mixed in Wednesday Trading; Sanofi to Acquire Dynavax Technologies - marketscreener.com
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal By Reuters - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sanofi paying $2.2B for Dynavax; tolebrutinib CRL lands - BioWorld MedTech
Dynavax Technologies Stock Soars on Buyout Buzz - Schaeffer's Investment Research
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio - Yahoo Finance
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion - Yahoo Finance
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying - Yahoo Finance
Watch Intel Declines; Dynavax Rallies; Nike Ticks Higher - Bloomberg.com
Intel Stock Slides as Nvidia Pauses 18A Testing; Nike Jumps on Tim Cook Buy and Dynavax Soars on Sanofi Deal - ts2.tech
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter - Stocktwits
Sanofi Buys Dynavax for $2.2 Billion to Boost Vaccine Lineup - Bloomberg.com
Dynavax Technologies stock hits 52-week high at 15.48 USD - Investing.com
Dynavax Technologies stock hits 52-week high at 15.48 USD By Investing.com - Investing.com Canada
Sanofi to Buy Dynavax in $2.2 Billion Cash Deal - marketscreener.com
Sanofi to acquire Dynavax in $2.2B deal to boost adult vaccines - Proactive financial news
Dynavax Technologies Corp Stock (DVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):